Evaluating Efficacy of Fumagilin-B® Against Nosemosis and Tracking Seasonal Trends of Nosema spp. in Nova Scotia Honey Bee Colonies
The efficacy of the antimicrobial Fumagilin-B against nosemosis was evaluated in both spring and autumn feeding treatments following label directions in seventy-two honey bee ( ) colonies across three apiaries in Nova Scotia, Canada. The seasonal trend of spp. spore loads was also tracked in these s...
Saved in:
Published in | Journal of Apicultural Science Vol. 64; no. 2; pp. 277 - 286 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Pulawy
Sciendo
01.12.2020
De Gruyter Poland |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The efficacy of the antimicrobial Fumagilin-B
against nosemosis was evaluated in both spring and autumn feeding treatments following label directions in seventy-two honey bee (
) colonies across three apiaries in Nova Scotia, Canada. The seasonal trend of
spp. spore loads was also tracked in these same colonies throughout a thirteen-month period (February 2018 – March 2019). We found the spring Fumagilin-B
treatment to be effective at significantly suppressing
spp. spore levels below the recommended treatment threshold. There was no effect of Fumagilin-B
treatment in the autumn based on low spore levels at this time. We detected a drastic increase in
spp. spore loads as May progressed but a decline in spores in summer (June–September). By October, there was another increase in spore levels, but this increase did not exceed the economic treatment threshold. Across seventeen collection periods in both control and Fumagilin-B
colonies, 74% (25) of samples tested positive for
, while 26% (9) contained no
spp. spores. No
spores were detected during this trial. Our results indicate that Fumagilin-B
is an effective management practice in the spring, but colonies should still be monitored in the autumn. Our data also support that the
species profile is shifting to be exclusively
and the treatment threshold for Fumagilin-B
may need to be updated to reflect this, as the threshold was originally developed for |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 2299-4831 1643-4439 2299-4831 |
DOI: | 10.2478/jas-2020-0025 |